Study of BGB-A317 in Participants With Previously Treated Unresectable HCC

PHASE2CompletedINTERVENTIONAL
Enrollment

249

Participants

Timeline

Start Date

April 9, 2018

Primary Completion Date

June 30, 2021

Study Completion Date

July 6, 2022

Conditions
Hepatocellular Carcinoma (HCC)
Interventions
DRUG

Tislelizumab

Administered intravenously

Trial Locations (54)

704

National Cheng Kung University Hospital, Tainan City

6200

Hopital Larchet Chu Nice, Nice

10048

National Taiwan University Hospital, Taipei

11217

Taipei Veterans General Hospital, Taipei

20089

Istituto Clinico Humanitas, Rozzano

20251

Universitatsklinikum Hamburg Eppendorf, Hamburg

28046

Hospital Universitario La Paz, Madrid

28050

Hospital Universitario Hm Madrid Sanchinarro, Madrid

33305

Linkou Chang Gung Memorial Hospital, Taoyuan District

33604

Groupe Hospitalier Du Haut Leveque, Pessac

34295

Chu Montpellier Hopital Saint Eloi, Montpellier

35043

Centre Eugene Marquis, Rennes

44093

Centre Hospitalier Universitaire Nantes Hotel Dieu, Nantes

45136

Kliniken Essen Mitte Evang Huyssens Stiftung, Essen

55131

Klinikum Johannes Gutenberg Universitaet Mainz, Mainz

56126

Azienda Ospedaliero Universitaria Pisana, Pisa

69317

Hopital de La Croix Rousse, Lyon

82445

E Da Hospital Kaohsiung, Kaohsiung City

86000

Chu de Poitiers Site de La Mileterie, Poitiers

92210

Hopital Beaujon, Clichy

94805

Institut Gustave Roussy, Villejuif

100039

Military Hospital of China, Beijing

100142

Beijing Cancer Hospital, Beijing

100853

Chinese Pla General Hospital, Beijing

130021

Jilin Cancer Hospital, Changchun

150000

Harbin Medical University Cancer Hospital, Harbin

200000

Fudan University Shanghai Cancer Center, Shanghai

200032

Affiliated Zhongshan Hospital of Fudan University, Shanghai

221000

Xuzhou Central Hospital, Xuzhou

230000

Anhui Provincial Hospital, Hefei

230601

The Second Hospital of Anhui Medical University, Hefei

261000

Weifang Peoples Hospital, Weifang

300060

Tianjin Medical University Cancer Institute and Hospital, Tianjin

310003

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

310009

Zhejiang University College of Medicine Second Affiliated Hospital, Hangzhou

310016

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou

310022

Zhejiang Cancer Hospital, Hangzhou

325000

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou

330006

The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang

The Second Affiliated Hospital of Nanchang University, Nanchang

430022

Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan

430079

Hubei Cancer Hospital, Wuhan

450000

Henan Cancer Hospital, Zhengzhou

510245

Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South), Guangzhou

510515

Nanfang Hospital of Southern Medical University, Guangzhou

518036

Peking University Shenzhen Hospital, Shenzhen

02-034

Narodowy Instytut Onkologii Im Marii Skodowskiej Curie Pastwowy Instytut Badawczy, Warsaw

08035

Hospital Universitario Vall Dhebron, Barcelona

08908

Ico Lhospitalet Hospital Duran I Reynals, Barcelona

B15 2TH

Queen Elizabeth Hospital, Birmingham

M20 4BX

The Christie Hospital, Greater Manchester

NW3 2QG

Royal Free Hospital London Nhs Trust, London

SE5 9RS

Kings College, London

NE7 7DN

Freeman Hospital, Newcastle upon Tyne

Sponsors

Lead Sponsor

All Listed Sponsors
lead

BeiGene

INDUSTRY